Brighton Jones LLC Invests $69,000 in Aldeyra Therapeutics, Inc. $ALDX

Brighton Jones LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 17,899 shares of the biotechnology company’s stock, valued at approximately $69,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC bought a new stake in Aldeyra Therapeutics during the first quarter valued at about $63,000. CWM LLC lifted its stake in shares of Aldeyra Therapeutics by 1,164.4% during the first quarter. CWM LLC now owns 19,244 shares of the biotechnology company’s stock worth $111,000 after buying an additional 17,722 shares during the period. XTX Topco Ltd acquired a new stake in shares of Aldeyra Therapeutics during the first quarter worth $134,000. Invesco Ltd. lifted its stake in shares of Aldeyra Therapeutics by 1,575.7% during the first quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company’s stock worth $2,882,000 after buying an additional 471,231 shares during the period. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Aldeyra Therapeutics during the first quarter worth $155,000. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Stock Up 0.8%

Shares of NASDAQ ALDX opened at $5.07 on Friday. The stock has a market capitalization of $303.69 million, a price-to-earnings ratio of -5.96 and a beta of 0.83. Aldeyra Therapeutics, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20. The firm has a 50-day simple moving average of $5.38 and a 200-day simple moving average of $4.24.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.05. As a group, equities research analysts expect that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ALDX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aldeyra Therapeutics in a report on Wednesday, October 8th. Zacks Research raised Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Insider Activity

In other news, insider Stephen Machatha sold 22,073 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $5.15, for a total transaction of $113,675.95. Following the completion of the sale, the insider owned 221,799 shares in the company, valued at $1,142,264.85. This trade represents a 9.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.60% of the stock is owned by corporate insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.